Identification
- Summary
Sibutramine is a norepinephrine, serotonin and dopamine reuptake inhibitor indicated to assist with weight loss in obesity.
- Generic Name
- Sibutramine
- DrugBank Accession Number
- DB01105
- Background
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.
- Type
- Small Molecule
- Groups
- Approved, Illicit, Investigational, Withdrawn
- Structure
Structure for Sibutramine (DB01105)
- Weight
- Average: 279.848
Monoisotopic: 279.175377544 - Chemical Formula
- C17H26ClN
- Synonyms
- Sibutramina
- Sibutramine
- Sibutraminum
- External IDs
- HSDB 7209
Pharmacology
- Indication
For the treatment of obesity.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to manage Bmi >30 kg/m2 •••••••••••• •••• ••• •••••••• ••• •••••••••• ••• •••••• •••• ••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Sibutramine is an orally administered agent for the treatment of obesity. Sibutramine exerts its pharmacological actions predominantly via its secondary (M1) and primary (M2) amine metabolites. The parent compound, sibutramine, is a potent inhibitor of serotonin and norepinephrine reuptake in vivo, but not in vitro. However, metabolites M1 and M2 inhibit the reuptake of these neurotransmitters both in vitro and in vivo. In human brain tissue, M1 and M2 also inhibit dopamine reuptake in vitro, but with ~3-fold lower potency than for the reuptake inhibition of serotonin or norepinephrine. Sibutramine, M1 and M2 exhibit no evidence of anticholinergic or antihistaminergic actions. In addition, receptor binding profiles show that sibutramine, M1 and M2 have low affinity for serotonin (5-HT1, 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C), norepinephrine (b, b1, b3, a1 and a2), dopamine (D1 and D2), benzodiazepine, and glutamate (NMDA) receptors. These compounds also lack monoamine oxidase inhibitory activity in vitro and in vivo.
- Mechanism of action
Sibutramine produces its therapeutic effects by inhibition of norepinephrine (NE), serotonin (5-hydroxytryptamine, 5-HT), and to a lesser extent, dopamine reuptake at the neuronal synapse. By inhibiting the reuptake of these neurotransmitters, sibutramine promotes a sense of satiety and decrease in appetite, thereby reducing food intake. Data from animal studies also suggest that sibutramine may also increase energy expenditure through thermogenic effects in both the basal and fed states, but this has not been confirmed in humans. Sibutramine and its major pharmacologically active metabolites (M1 and M2) do not act via release of monoamines.
Target Actions Organism ASodium-dependent dopamine transporter inhibitorHumans ASodium-dependent serotonin transporter inhibitorHumans ASodium-dependent noradrenaline transporter inhibitorHumans - Absorption
Rapid absorption following oral administration. Absolute bioavailability is not known, but at least 77% of a single oral dose of sibutramine is absorbed.
- Volume of distribution
Not Available
- Protein binding
97% (to human plasma proteins)
- Metabolism
Hepatic
- Route of elimination
Sibutramine is metabolized in the liver principally by the cytochrome P450 (3A4) isoenzyme, to desmethyl metabolites, M1 and M2. These active metabolites are further metabolized by hydroxylation and conjugation to pharmacologically inactive metabolites, M5 and M6. Approximately 85% (range 68-95%) of a single orally administered radiolabeled dose was excreted in urine and feces over a 15-day collection period with the majority of the dose (77%) excreted in the urine. The primary route of excretion for M1 and M2 is hepatic metabolism and for M5 and M6 is renal excretion.
- Half-life
1.1 hours
- Clearance
- Oral cl=1750 L/h [oral administration]
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Side effects include dry mouth, anorexia, insomnia, constipation and headache.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 --- (T;T) / (C;T) C > T Effect Directly Studied Patients with this genotype will lose weight with sibutramine. Details
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when 1,2-Benzodiazepine is combined with Sibutramine. Abacavir Abacavir may decrease the excretion rate of Sibutramine which could result in a higher serum level. Abametapir The serum concentration of Sibutramine can be increased when it is combined with Abametapir. Abciximab The risk or severity of hemorrhage can be increased when Sibutramine is combined with Abciximab. Acebutolol The serum concentration of Acebutolol can be increased when it is combined with Sibutramine. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Sibutramine hydrochloride OGM0YHD1WF 125494-59-9 KFNNPQDSPLWLCX-UHFFFAOYSA-N - International/Other Brands
- Butramin / Medaria / Reductil
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Meridia Capsule 10 mg Oral Abbott 2001-02-28 2010-10-12 Canada 
Meridia Capsule 5 mg/1 Oral AbbVie Inc 2010-08-12 2010-12-21 US 
Meridia Capsule 15 mg/1 Oral AbbVie Inc 2010-08-12 2012-12-21 US Meridia Capsule 15 mg Oral Abbott 2001-02-28 2010-10-12 Canada Meridia Capsule 10 mg/1 Oral AbbVie Inc 2010-08-12 2012-12-21 US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Apo-sibutramine Capsule 10 mg Oral Apotex Corporation 2009-11-23 2010-10-12 Canada Apo-sibutramine Capsule 15 mg Oral Apotex Corporation 2009-11-23 2010-10-12 Canada
Categories
- ATC Codes
- A08AA10 — Sibutramine
- Drug Categories
- Agents producing tachycardia
- Alimentary Tract and Metabolism
- Anti-Obesity Agents
- Antidepressive Agents
- Antiobesity Preparations, Excl. Diet Products
- Appetite Depressants
- Appetite Suppression
- Central Nervous System Agents
- Central Nervous System Depressants
- Centrally Acting Antiobesity Products
- Combined Inhibitors of Serotonin/Norepinephrine Reuptake
- Cycloparaffins
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Substrates
- Dopamine Uptake Inhibitors
- Drugs that are Mainly Renally Excreted
- Norepinephrine Uptake Inhibitors
- Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic
- Psychotropic Drugs
- Selective Serotonin Reuptake Inhibitors
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Serotonin Agents
- Serotonin and Noradrenaline Reuptake Inhibitors
- Serotonin Modulators
- Stimulants
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Halobenzenes
- Direct Parent
- Chlorobenzenes
- Alternative Parents
- Aralkylamines / Aryl chlorides / Trialkylamines / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
- Substituents
- Amine / Aralkylamine / Aromatic homomonocyclic compound / Aryl chloride / Aryl halide / Chlorobenzene / Hydrocarbon derivative / Organic nitrogen compound / Organochloride / Organohalogen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- tertiary amino compound, organochlorine compound (CHEBI:9137)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- WV5EC51866
- CAS number
- 106650-56-0
- InChI Key
- UNAANXDKBXWMLN-UHFFFAOYSA-N
- InChI
- InChI=1S/C17H26ClN/c1-13(2)12-16(19(3)4)17(10-5-11-17)14-6-8-15(18)9-7-14/h6-9,13,16H,5,10-12H2,1-4H3
- IUPAC Name
- {1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}dimethylamine
- SMILES
- CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1
References
- Synthesis Reference
Chris Senanayake, "Methods of preparing didesmethylsibutramine and other sibutramine derivatives." U.S. Patent US20020183554, issued December 05, 2002.
US20020183554- General References
- Sharma B, Henderson DC: Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother. 2008 Aug;9(12):2161-73. doi: 10.1517/14656566.9.12.2161 . [Article]
- Tziomalos K, Krassas GE, Tzotzas T: The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag. 2009;5(1):441-52. [Article]
- Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC: Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord. 1998 Aug;22 Suppl 1:S18-28; discussion S29. [Article]
- Stock MJ: Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord. 1997 Mar;21 Suppl 1:S25-9. [Article]
- External Links
- Human Metabolome Database
- HMDB0015237
- KEGG Drug
- D08513
- KEGG Compound
- C07247
- PubChem Compound
- 5210
- PubChem Substance
- 46507740
- ChemSpider
- 5021
- BindingDB
- 84742
- 36514
- ChEBI
- 9137
- ChEMBL
- CHEMBL1419
- Therapeutic Targets Database
- DCL000881
- PharmGKB
- PA451344
- Guide to Pharmacology
- GtP Drug Page
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Sibutramine
- FDA label
- Download (134 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Treatment Bipolar Disorder (BD) / Psychosis / Schizophrenia 1 4 Completed Treatment Eating, Binge / Obesity 1 4 Completed Treatment Hypertension / Obesity / Obstructive Sleep Apnea (OSA) 1 4 Completed Treatment Obesity 3 4 Completed Treatment Obesity / Polycystic Ovarian Syndrome (PCOS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Abbott Laboratories Ltd.
- Apotheca Inc.
- A-S Medication Solutions LLC
- BASF Corp.
- Bryant Ranch Prepack
- Dispensing Solutions
- PD-Rx Pharmaceuticals Inc.
- Physicians Total Care Inc.
- Dosage Forms
Form Route Strength Capsule Oral 10 mg Capsule Oral 10 mg/1 Capsule Oral 15 mg Capsule Oral 15 mg/1 Capsule Oral 5 mg/1 Capsule, coated Oral 5 mg Capsule Oral Capsule, coated Oral 20 mg Capsule, coated Oral 10 mg Capsule, coated Oral 15 mg - Prices
Unit description Cost Unit Meridia 15 mg capsule 5.11USD capsule Meridia 10 mg capsule 4.02USD capsule Meridia 5 mg capsule 4.0USD capsule DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5436272 No 1995-07-25 2013-01-25 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 191-192 °C Not Available water solubility 2.9 mg/mL (in pH 5.2 water) Not Available logP 5.2 Not Available - Predicted Properties
Property Value Source Water Solubility 0.00094 mg/mL ALOGPS logP 5.05 ALOGPS logP 5.2 Chemaxon logS -5.5 ALOGPS pKa (Strongest Basic) 9.77 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 3.24 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 83.92 m3·mol-1 Chemaxon Polarizability 32.9 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9948 Blood Brain Barrier + 0.9667 Caco-2 permeable + 0.6584 P-glycoprotein substrate Non-substrate 0.5148 P-glycoprotein inhibitor I Non-inhibitor 0.718 P-glycoprotein inhibitor II Inhibitor 0.5071 Renal organic cation transporter Non-inhibitor 0.5805 CYP450 2C9 substrate Non-substrate 0.8056 CYP450 2D6 substrate Non-substrate 0.9115 CYP450 3A4 substrate Substrate 0.6969 CYP450 1A2 substrate Non-inhibitor 0.7059 CYP450 2C9 inhibitor Non-inhibitor 0.9205 CYP450 2D6 inhibitor Non-inhibitor 0.754 CYP450 2C19 inhibitor Non-inhibitor 0.7041 CYP450 3A4 inhibitor Non-inhibitor 0.969 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8292 Ames test Non AMES toxic 0.837 Carcinogenicity Non-carcinogens 0.5808 Biodegradation Not ready biodegradable 0.9903 Rat acute toxicity 2.9056 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9065 hERG inhibition (predictor II) Inhibitor 0.769
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 168.7428162 predictedDarkChem Lite v0.1.0 [M-H]- 176.19402 predictedDeepCCS 1.0 (2019) [M+H]+ 169.3326162 predictedDarkChem Lite v0.1.0 [M+H]+ 178.55203 predictedDeepCCS 1.0 (2019) [M+Na]+ 169.0024162 predictedDarkChem Lite v0.1.0 [M+Na]+ 184.64519 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Monoamine transmembrane transporter activity
- Specific Function
- Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
- Gene Name
- SLC6A3
- Uniprot ID
- Q01959
- Uniprot Name
- Sodium-dependent dopamine transporter
- Molecular Weight
- 68494.255 Da
References
- Tziomalos K, Krassas GE, Tzotzas T: The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag. 2009;5(1):441-52. [Article]
- Gomis Barbara R: [Pharmacological treatment of obesity]. Rev Med Univ Navarra. 2004 Apr-Jun;48(2):63-5. [Article]
- Berke EM, Morden NE: Medical management of obesity. Am Fam Physician. 2000 Jul 15;62(2):419-26. [Article]
- Nakagawa T, Ukai K, Ohyama T, Gomita Y, Okamura H: Effects of sibutramine on the central dopaminergic system in rodents. Neurotox Res. 2001 Jul;3(3):235-47. [Article]
- Krahn LE, Moore WR, Altchuler SI: Narcolepsy and obesity: remission of severe cataplexy with sibutramine. Sleep Med. 2001 Jan;2(1):63-65. [Article]
- Balcioglu A, Wurtman RJ: Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid. Neuropharmacology. 2000 Sep;39(12):2352-9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serotonin:sodium symporter activity
- Specific Function
- Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
- Gene Name
- SLC6A4
- Uniprot ID
- P31645
- Uniprot Name
- Sodium-dependent serotonin transporter
- Molecular Weight
- 70324.165 Da
References
- Vazquez Roque MI, Camilleri M, Clark MM, Tepoel DA, Jensen MD, Graszer KM, Kalsy SA, Burton DD, Baxter KL, Zinsmeister AR: Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine. Clin Gastroenterol Hepatol. 2007 Jul;5(7):829-37. Epub 2007 Jun 4. [Article]
- Heusser K, Engeli S, Tank J, Diedrich A, Wiesner S, Janke J, Luft FC, Jordan J: Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. J Clin Endocrinol Metab. 2007 Apr;92(4):1560-3. Epub 2007 Feb 6. [Article]
- Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM: Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes (Lond). 2005 May;29(5):509-16. [Article]
- Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Kruger N, Strauss A, Stoffels G, Luft FC, Jordan J: Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther. 2006 May;79(5):500-8. [Article]
- Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J: Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation. 2002 Nov 5;106(19):2459-65. [Article]
- Birkenfeld AL, Schroeder C, Pischon T, Tank J, Luft FC, Sharma AM, Jordan J: Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure. Clin Auton Res. 2005 Jun;15(3):200-6. [Article]
- Tziomalos K, Krassas GE, Tzotzas T: The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag. 2009;5(1):441-52. [Article]
- Sharma B, Henderson DC: Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother. 2008 Aug;9(12):2161-73. doi: 10.1517/14656566.9.12.2161 . [Article]
- Gomis Barbara R: [Pharmacological treatment of obesity]. Rev Med Univ Navarra. 2004 Apr-Jun;48(2):63-5. [Article]
- Berke EM, Morden NE: Medical management of obesity. Am Fam Physician. 2000 Jul 15;62(2):419-26. [Article]
- Krahn LE, Moore WR, Altchuler SI: Narcolepsy and obesity: remission of severe cataplexy with sibutramine. Sleep Med. 2001 Jan;2(1):63-65. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Norepinephrine:sodium symporter activity
- Specific Function
- Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
- Gene Name
- SLC6A2
- Uniprot ID
- P23975
- Uniprot Name
- Sodium-dependent noradrenaline transporter
- Molecular Weight
- 69331.42 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Heusser K, Engeli S, Tank J, Diedrich A, Wiesner S, Janke J, Luft FC, Jordan J: Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. J Clin Endocrinol Metab. 2007 Apr;92(4):1560-3. Epub 2007 Feb 6. [Article]
- Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM: Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes (Lond). 2005 May;29(5):509-16. [Article]
- Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Kruger N, Strauss A, Stoffels G, Luft FC, Jordan J: Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther. 2006 May;79(5):500-8. [Article]
- Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J: Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation. 2002 Nov 5;106(19):2459-65. [Article]
- Birkenfeld AL, Schroeder C, Pischon T, Tank J, Luft FC, Sharma AM, Jordan J: Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure. Clin Auton Res. 2005 Jun;15(3):200-6. [Article]
- Tziomalos K, Krassas GE, Tzotzas T: The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag. 2009;5(1):441-52. [Article]
- Sharma B, Henderson DC: Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother. 2008 Aug;9(12):2161-73. doi: 10.1517/14656566.9.12.2161 . [Article]
- Gomis Barbara R: [Pharmacological treatment of obesity]. Rev Med Univ Navarra. 2004 Apr-Jun;48(2):63-5. [Article]
- Berke EM, Morden NE: Medical management of obesity. Am Fam Physician. 2000 Jul 15;62(2):419-26. [Article]
- Krahn LE, Moore WR, Altchuler SI: Narcolepsy and obesity: remission of severe cataplexy with sibutramine. Sleep Med. 2001 Jan;2(1):63-65. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Sharma B, Henderson DC: Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother. 2008 Aug;9(12):2161-73. doi: 10.1517/14656566.9.12.2161 . [Article]
- Luque CA, Rey JA: Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother. 1999 Sep;33(9):968-78. doi: 10.1345/aph.18319. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 02, 2024 22:55